Neuropharmacology of cannabinoid system: From basic science to clinical applications

Current Neuropharmacology

Volumn 2, Issue 1, 2004, Pages 1-7

  Buttarelli, F R ^a   Patacchioli, F R ^b   Palladini, G ^a   Brunetti, E ^c   Pontieri, Francesco E ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Analgesia; Cannabinoid receptors; Cannabis; Drug abuse; Memory impairment; Neurotransmitter release; Spasticity

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 AMINOBUTYRIC ACID; 4 AMINOPYRIDINE; ACETYLCHOLINE; ADENYLATE CYCLASE; ANANDAMIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; BARIUM CHLORIDE; CADMIUM; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CYCLIC AMP; FORSKOLIN; GLUTAMIC ACID; ION CHANNEL; LEVODOPA; LIGAND; NABILONE; NEUROTRANSMITTER; OPIATE; OPIATE RECEPTOR; PRESYNAPTIC RECEPTOR; REACTIVE OXYGEN METABOLITE; RECEPTOR SUBTYPE; RIMONABANT; UNINDEXED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; ANOREXIA; BRAIN DEPTH STIMULATION; BRAIN DYSFUNCTION; CENTRAL NERVOUS SYSTEM FUNCTION; DRUG ABUSE; DRUG DEPENDENCE; DYSKINESIA; HUMAN; KNOCKOUT MOUSE; MEMORY DISORDER; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRESYNAPTIC NERVE; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SYNAPTIC TRANSMISSION; VOMITING;

EID: 3042651006     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159043476981     Document Type: Review

References (94)

1. Ameri, A. (1999) The effects of cannabinoids in the brain. Progress in Neurobiology, 58, 315-348
2. Auclair, N., Otani, S., Soubrie, P., Crepel, F. (2000) Cannabinoids modulate synaptic strenght and plasticity at glutamatergic synapses of the rat prefrontal cortex pyramidal neurons. Journal of Neurophysiology, 83, 3287-3293
3. Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee, R.G., Huffman, J.W., Layward, L. (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature, 404, 84-87
4. Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee. R.G., Makriyannis. A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., Di Marzo, V. (2001) Endocannabinoids control spasticity and tremor in a multiple sclerosis model. FASEB Journal, 15, 300-302
5. Beltramo, M., Stella, N., Calignano, A., Lin, S.Y., Makriyannis, A., Piomelli, D. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277, 1094-1097
6. Boger, D.L., Sato, H., Lerner, A.E., Hedrick, M.P., Fecik, R.A., Miyauchi, H., Wolie, G.D., Austin, B.J., Patricelli, M.P., Cravatt, B.F. (2000) Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proceedings of the National Academy of Sciences USA, 97, 5044-5049
7. Buttarelli, F.R., Pontieri, F.E., Margotta, V., Palladini, G. (2002) Stimulation of motor activity by WIN55212.2 in planaria by an opioid receptor-mediated mechanism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26, 65-68
8. Cadoni, C., Pisanu, A., Solinas, M., Acquas, E., Di Chiara, G. (2001) Behavioural sensitization after repeated exposure to delta(9)-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology, 158, 259-266
9. Calignano, A., La Rana, G, Giuffrida, A., Piomelli, D. (1998) Control of pain initiation by endogenous cannabinoids. Nature, 394, 277-281
10. Chan, P.K.J., Yung, W.H. (1998) Occlusion of the presynatic action of cannabinoids in rat substantia nigra pars reticulata by cadmium. Neuroscience Letters, 249, 57-60
11. Cheer, J.F., Marsden, C.A., Kendall, D.A., Mason, R. (2000) Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study. Neuroscience, 99, 661-667
12. Christopoulos, A., Coles, P., Lay, L., Lew, M.J., Angus, J.A. (2001) Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. British Journal of Pharmacology, 132, 1281-1291
13. Consroe, P., Musty, R., Rein, J., Tillery, W., Pertwee, R. (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology, 38, 44-48
14. 2+ and cAMP. Canadian Journal of Physiology and Pharmacology, 76, 340-346
15. 1 receptors in the human ileum. British Journal of Pharmacology, 125, 1393-1395
16. Degenhardt, L., Hall, W. (2002) Cannabis and psychosis. Current Psychiatry Reports, 4, 191-196
17. Deutsch, D.G., Goligorsky, M.S., Schmid, P.C., Krebsbach, R.J., Schmid, H.H., Das, S.K., Dey, S.K., Arreaza, G., Thorup, C., Stefano, G., Moore, L.C. (1997) Production and physiological actions of anandamide in the vasculature of the rat kidney. Journal of Clinical Investigation, 100, 1538-1546
18. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R.l. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptors. Science, 258, 1946-1949
19. Deutsch, D.G., Ueda, N, Yamamoto, S. (2002) The fatty acid amide hydrolase (FAAH). Prostaglandins, Leukotrienes and Essential Fatty Acids, 66, 201-210
20. Di Chiara, G., Imperato, A. (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences USA, 85, 5274-5278
21. Di Chiara, G. (1999) Drug addiction as dopamine-dependent associative learning disorder. European Journal of Pharmacology, 375, 13-30.
22. Dinh, T.P., Freund, T.F., Piomelli, D. (2002) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chemistry and Physics of Lipids, 121, 149-158
23. Dutar, P, Bassant, M.H., Senut, M.C., Lamour, Y. (1995) The septohippocampal pathway: structure and function of a central cholinergic system. Physiological Reviews, 75, 393-427
24. Emilien, G., Beyreuther, K., Masters, C.L., Maloteaux, J.M. (2000) Prospects for the pharmacological intervention in Alzheimer's disease. Archives of Neurology, 57, 454-459
25. Fezza, F., Bisogno, T., Minassi, A., Appendino, G., Mechoulam, R., Di Marzo, V. (2002) Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method quantification in rat tissues. FEBS Letters, 513, 294-298
26. Fowler, C.J. (2003) Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents: non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid psychotropic effects. Brain Research Reviews, 41, 26-43
27. French, E.D., Dillon, K., Wu, X. (1997) Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. NeuroReport, 8, 649-652
28. Gardner, E.L., Vorel, S.R. (1998) Cannabinoid transmission and reward-related events. Neurobiology of Disease, 5, 502-533
29. Gessa, G.L., Mascia, M.S., Casu, M.A., Carta, G. (1997) Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. European Journal of Pharmacology, 327, R1-R2
30. Gessa, G.L., Melis, M., Muntoni, A.L., Diana, M. (1998) Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. European Journal of Pharmacology, 341, 39-44
31. Gifford, A.N., Ashby, C.R. (1996) Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN55,212-2, and is potentiated by the cannabinoid antagonist, SR141716A. Journal of Pharmacology and Experimental Therapeutics, 277, 1431-1436
32. Gifford, A.N., Bruneus, M., Lin, S., Goutopoulos, A., Makriyannis, A., Volkow, N.D., Gatley, S.J. (1999) Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). European Journal of Pharmacology, 383, 9-14
33. Gill, E.W., Paton, W.D., Pertwee, R.G. (1970) Preliminary experiments on the chemistry and pharmacology of cannabis. Nature, 228, 134-136
34. Giuffirida, A., Parsons, L.H., Kerr, T.M., Rodriguez de Fonseca, F., Navarro, M., Piomelli, D. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience, 2, 358-363
35. Glass, M., Dragunow, M., Faull, R.L. (2000) The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntignton's disease. Neuroscience, 97, 505-519
36. 3H]noradrenaline from mouse cultured sympathetic neurons: release-modulating heteroreceptors. Journal of Neurochemistry, 75, 2087-2094
37. Grundy, R.I. (2002) The therapeutic potential of the cannabinoids in neuroprotection. Expert Opinion in Investigational Drugs, 11, 1365-1374
38. Hall, W., Solowji, N. (1998) Adverse effects of cannabis. Lancet, 352, 1611-1616
39. Hajos, N., Katona, I., Naiem, S.S., MacKie, K., Ledent, C., Mody, I., Freund, T.F. (2001) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. European Journal of Neuroscience, 12, 3239-3249
40. Hawks, R.L. (1982) The constituents of cannabis and the disposition and metabolism of cannabinoids. NIDA Research Monographs, 42, 125-137
41. Herkenham, M., Groen, B.G., Lynn, A.B., De Costa, B.R., Richfield, E.K. (1991) Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Research, 552, 301-310
42. Hoffman, A.F., Lupica, C.R. (2000) Mechanisms of cannabinoid inhibition of GABAA synaptic transmission in the hippocampus. Journal of Neuroscience, 20, 2470-2479
43. Hoffman, A.F., Lupica, C.R. (2001) Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. Journal of Neurophysiology, 85, 72-83
44. Hohmann, A.G. (2002) Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chemistry and Physics of Lipids, 121, 173-190
45. Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R., Pertwee, R.G. (2002) International Union of Pharmacology: XXVII, classification of cannabinoid receptors. Pharmacological Reviews, 54, 161-202
46. Huang, C.C., Lo, S.W., Hsu, K.S. (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. Journal of Physiology (London), 532, 731-748
47. 1 receptor-deficient mice. British Journal of Pharmacology, 132, 1169-1173
48. 1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 363, 50-56
49. Katona, I., Sperlagh, B., Magloczky, Z., Santha, E., Kofalvi, A., Czirjak, S., Mackie, K., Vizi, E.S., Freund, T.F. (2000) GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience, 100, 797-804
50. Kent, J.M. (2000) SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet, 355, 911-918
51. Kreitzer, A.C., Regehr, W.G. (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron, 29, 717-727
52. Kumar, R.N., Chambers, W.A., Pertwee, R.G. (2001) Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia, 56, 1059-1068
53. Lazareno, S., Popham, A., Birdsall, N.J. (2000) Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Molecular Pharmacology, 58, 194-207
54. Lichtman, A.H., Dimen, K.R., Martin, B.R. (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology, 119, 282-290
55. Manzoni, O.J., Bockaert, J. (2001) Cannabinoids inhibit GABAergic synaptic transmission in the mouse nucleus accumbens. European Journal of Pharmacology, 412, R3-R5
56. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564
57. Mechoulam, R. (1986) The pharmacohistory of Cannabis sativa. In: Mechoulam, R., Ed, Cannabinoids as therapeutic agents. Boca Raton, CRC Press, pp 1-19
58. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R, Pertwee, R.G., Griffin, G., Bayewitch, M, Barg, J, Vogel, Z, (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50, 83-90
59. Misner, D.L., Sullivan, J.M. (1999) Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. Journal of Neuroscience, 19, 6795-6805
60. Molderings, G.J., Likungu, J., Gothert, M. (1999) Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn-Schmiedeberg's Archives of Pharmacology, 360, 157-164
61. Muller-Vahl, K.R., Schneider, U., Koblenz, A., Jobges, M., Kolbe, H., Daldrup, T., Emrich, H.M. (2002) Treatment of Tourette's syndrome with Delta-9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry, 35, 57-61
62. Munro, S., Thomas, K.L., Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65
63. Nagayama, T., Sinor, A.D., Simon, R.P., Chen, J., Graham, S.H., Jin, K., Greenberg, D.A. (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. Journal of Neuroscience, 19, 2987-2995
64. Ohnu-Shosaku, T., Maejima, T., Kano, M. (2001) Endogenous cannabinoids mediate retrograde signals from depolaryzed postsynaptic neurons to presynaptic terminals. Neuron, 29, 729-738
65. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., Shohami, E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 413, 527-531
66. 2 receptors. Pharmacology and Therapeutics, 74, 129-180
67. Pertwee, R.G. (1999) Pharmacology of the cannabinoid receptor ligands. Current Medical Chemistry, 6, 635-664
68. Pontieri, F.E., Tanda, G., Di Chiara, G. (1995) Intravenous cocaine, morphine and amphetamine preferentially increase extracellular dopamine concentration in the "shell" as compared to the " core" of the rat nucleus accumbens. Proceedings of the National Academy of Sciences USA, 92, 12304-12308
69. Pontieri, F.E., Conti, G., Zocchi, A, Fieschi, C., Orzi, F. (1999) Metabolic mapping of the effects of WIN55212.2 intravenous administration in the rat. Neuropsychopharmacology, 21, 773-776
70. Pontieri, F.E., Monnazzi, P., Scontrini, A., Buttarelli, F.R., Patacchioli, F.R. (2001a) Behavioral sensitization to WIN55212.2 in rats pretreated with heroin. Brain Research, 898, 178-180
71. Pontieri, F.E., Monnazzi, P., Scontrini, A., Buttarelli, F.R., Patacchioli, F.R. (2001b) Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. European Journal of Pharmacology, 421, R1-R3
72. Robbe, D., Alonso, G., Duchamp, F., Bockaert, J., Manzoni, O.J. (2001) Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the nucleus accumbens. Journal of Neuroscience, 21, 109-116
73. Salzer, M., Stefano, G.B. (2002) The endocannabinoid system in invertebrates. Prostaglandins, Leukotrienes and Essential Fatty Acid, 66, 353-361
74. Schlicker, E., Timm, J., Gothert, M. (1996) Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn-Schmiedeberg's Archives of Pharmacology, 354, 791-795
75. 1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn-Schmiedeberg's Archives of Pharmacology, 356, 583-589
76. Schlicker, E., Kathmann, M. (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends in Pharmacological Sciences, 22, 565-572
77. Shen, M., Piser, T.M., Seybold, V.S., Thayer, S.A. (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. Journal of Neuroscience, 16, 4322-4334
78. Sieradzan, K.A., Fox, S.H., Hill, M., Dick, J.P., Crossman, A.R., Brotchie, J.M. (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology, 57, 2108-2111
79. Spanagel, R., Weiss, F. (1999) The dopamine hypothesis of reward: past and current status. Trends in Neuroscience, 22, 521-527
80. Stefano, G.B., Salzet, B., Rialas, C.M., Pope, M., Kustka, A., Neenan, K., Pryor, S., Salzer, M. (1997) Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release. Brain Research, 763, 63-68
81. Sullivan, J.M. (1999) Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal cells. Journal of Neurophysiology, 82, 1286-1294
82. Sullivan, J.M. (2000) Cellular and molecular mechanisms underlying learning and memory impairment produced by cannabinoids. Learning and Memory, 7, 132-139
83. Sugiura, T., Kobayashi, Y., Oka, S., Waku, K. (2002) Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins, Leukotrienes and Essential Fatty Acids, 66: 173-192
84. Szabo, B., Muller, T., Koch, H. (1999) Effects of cannabinoids on dopamine release in the corpus striatum and nucleus accumbens in vitro. Journal of Neurochemistry, 73, 1084-1089
85. Takahashi, K.A., Linden, D.J. (2000) Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. Journal of Neurophysiology, 83, 1167-1180
86. 1 opioid receptor mechanism. Science, 276, 2048-2050
87. Tian, W.N., Miller, D.D., Deth, R.C. (2000) Bidirectional allosteric effects of agonists and GTP at alpha(2A/D)-adrenoreceptors. Journal of Pharmacology and Experimental Therapeutics, 292, 664-671
88. Van Os, J., Bak, M., Hanssen, M., Bijl, R.V., De Graaf, R., Verdoux, H. (2002) Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology, 156: 319-327
89. Walker, J., Huang, S (2002) Cannabinoid analgesia. Pharmacology and Therapy, 95, 127-135
90. Walker, JM., Krey, J.F., Chu, C.J., Huang, S.M. (2002) Endocannabinoids and related fatty acid derivatives in pain modulation. Chemistry and Physics of Lipids, 121, 159-172
91. Watson, S.J., Benson, J.A. Jr., Joy, J.E. (2000) Marijuana and medicine: assessing the science base. A summary of the 1999 Institute of Medicine report. Archives of General Psychiatry, 57, 547-552
92. Wilson, R.I., Nicoll, R.A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 410, 588-592
93. Wilson, R.I. Nicoll, R.A. (2002) Endocannabinoid signalling in the brain. Science, 296, 678-682
94. Wong, D.T., Bymaster, F.P., Engleman, E.A. (1995) Prozac (fluoxetine, Lilly 110140), the first selctive serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sciences, 57, 411-441.